NICE hones medtech needs of unknown-origin cancers
This article was originally published in Clinica
Executive Summary
The UK’s National Institute for Health and Clinical Excellence (NICE) has issued new guidelines on the management of cancers of unknown primary origin (CUP), with the aim of better harnessing new diagnostic technologies and treatments.